Comparative evaluation of the concomitant four-component antihelicobacter therapy eradication effectiveness

Chernukha Sergey Nikolaevich, Viltsaniuk Irina Aleksandrovna

To study the eradication effectiveness of one–week four-component concomitant therapy without colloidal bismuth, depending on the choice of a proton pump inhibitor - esomeprazole or pantoprazole, the results of treatment of 132 patients with newly diagnosed H. pylori infection aged 21 to 59 years with verified peptic ulcers (and chronic gastritis) were analyzed. The main group included 68 patients, who received 7-day four-component concomitant therapy without colloidal bismuth: esomeprazole 40 mg twice a day, amoxicillin 1 g twice a day, metronidazole 500 mg twice a day, and clarithromycin 500 mg twice a day for 7 days, and in the control group, 64 patients received a similar antimicrobial regimen, but pantoprazole 40 mg twice a day was prescribed as acid suppression. The eradication effectiveness of the four-component concomitant one-week regimen in the main group, including esomeprazole, amoxicillin, clarithromycin and metronidazole was 91.2%, which is unreliably higher (p>0.05) than the results obtained during the treatment with the eradication regimen in the control group using pantoprazole (82.8%). Concomitant four-component, one-week, non- bismuth therapy allows for a high percentage of eradication as a first-line regimen, both due to a combination of antimicrobial drugs and due to the effective suppression of gastric acidity of esomeprazole, as well as avoiding a large number of side effects.

Keywords:Helicobacter pylori, esomeprazole, pantoprazole, antihelicobacter therapy, eradication.